Press Release

Brisbane, Australia, 24 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Phenix Health Pty Ltd, mobile clinic software developers and providers of an online virtual clinic, have entered into a joint development agreement (JDA) to integrate ResApp’s acute respiratory diagnostic test, ResAppDx-EU into Phenix’s telehealth smartphone app. Respiratory disease is involved in up to half of all telehealth consultations and ResAppDx-EU is the only solution for accurately diagnosing respiratory disease during a telehealth consultation that does not require additional hardware.

“Telehealth is emerging as a key tool in tackling the COVID-19 pandemic and Phenix Health is well-positioned to provide a valuable service to the Australian community,” said Dr Gillian Alexis, CEO and founder of Phenix Health. “Phenix provides video consultations to patients across Australia and, since the beginning of this crisis, we have seen a 30% month-on-month increase in the number of consultations. Our virtual clinic can be accessed nationwide through HealthEngine or directly via our downloadable app, and for patients told to self-isolate for possible COVID-19, these consultations are reimbursable under the MBS scheme. Phenix knows that implementing a telehealth service for patients must go beyond the limits of consumer video chat platforms like Skype which is why we are working with ResApp to bring their advanced diagnostic tool to our platform.”

ResAppDx-EU is a software application used by clinicians to diagnose the most common respiratory diseases. The software uses machine learning algorithms that analyse a patient’s cough sounds to diagnose lower respiratory tract diseases such as pneumonia and asthma exacerbations. ResAppDx-EU is CE Marked in the European Union and Therapeutics Goods Administration (TGA) approved in Australia.

Tony Keating, CEO and Managing Director of ResApp, added, “We are excited to be working with Phenix to enhance their service. ResAppDx-EU offers the only solution to accurately diagnose respiratory conditions through telehealth and will provide telehealth clinicians with a remote testing capability to help manage the COVID-19 pandemic. By assisting general practitioners (GPs) to evaluate patient symptoms during a telehealth consultation, in particular if an infection has reached the patient’s lungs, GPs will be better able to determine whether a patient should attend a hospital or clinic for additional care, conserving strained healthcare resources.”

Phenix and ResApp will work together under the JDA for the next three months to integrate ResAppDx-EU into Phenix’s telehealth app. During this time, ResApp and Phenix will negotiate the specifics of the fee-per-test payment model of using ResAppDx-EU on the Phenix App.

About Phenix Health Pty Ltd
Phenix Health Pty Ltd (ACN 607 559 423) is an integrative medical tech company founded in 2015 as a spin-off from our Australia-wide after-hours home visit doctor service where it was evidenced that large sectors of the population were not able to access adequate healthcare services. Phenix worked towards developing and refining our mobile technology, remote patient monitoring and telehealth service that assists connect both health professionals to their patient. Our mobile technology includes many clinical operational features providing a powerful collaborative tool for health care providers in: clinic, aged care facilities, emergency services, hospitals and remote and mobile settings. Phenix Health solves the disconnect between vertical digital health silos. Our team has come together through years of experience in developing and operating 24/7 health care services across metro and regional. For more information, please visit https://phenixhealth.com.au/.

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis, croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp’s smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit www.resapphealth.com.au